The effects of lobeglitazone on glycaemic control and lipid metabolism in high-fat diet-induced diabetic mice
- Author(s)
- H. Kim; N. Cho; E. Han; J.-H. Park; H. Cho
- Keimyung Author(s)
- Cho, Ho Chan; Park, Jae Hyung
- Department
- Dept. of Internal Medicine (내과학)
Dept. of Physiology (생리학)
- Journal Title
- Diabetologia
- Issued Date
- 2017
- Volume
- 60
- Issue
- 233
- Abstract
- Background and aims: The aim of this study was to compare the effects
of lobeglitazone, a novel peroxisome proliferator-activated receptor-γ
agonist, on glycemic control and lipid metabolism with pioglitazone in
mice with type 2 diabetes.We also determined the effects of lobeglitazone
and pioglitazone on glucose uptake, translocation of GLUT4 and AMPK
activity in 3T3L-1 adipocytes.
Materials and methods: 4-week-old C57BL/6 mice were treated with a
high-fat diet for 8 weeks. After 8 weeks of high-fat diet, lobeglitazone or
pioglitazone was administered once daily by oral gavage for 6 weeks.
Results: Low-dose lobeglitazone (1 mg/kg) improved fasting blood glucose
and insulin levels, HOMA-IR index, and blood triglyceride levels
while low-dose pioglitazone did not. In 3T3L-1 cells, low-dose
lobeglitazone (1 μM) significantly increased cellular glucose uptake
and, GLUT4 translocation. Pioglitzone exhibited similar effects at only
high dose treatment (10 μM). High-dose lobeglitazone (10 μM) increased
total cellular GLUT4 protein content while pioglitazone did not. In subcutaneous
fat and 3T3L-1 cells, relativemRNA expression levels for lipid
synthesis were increased in both lobeglitazone and pioglitazone-treated
groups compared to vehicle-treated group, but mRNA expression levels
of β-oxidation-related genes and the energy expenditure-related genes
were significantly increased in lobeglitazone-treated group compared to
pioglitazone-treated group. In addition, lobegitazone treatment significantly
increased phosphorylation of the AMP-activated protein kinase
compared to pioglitazone treatment in 3T3L-1 cells.
Conclusion: These results indicate that low-dose treatment of
lobeglitazone might be enough to improve glucose intolerance while
pioglitazone dose not. In addition, lobeglitazone could improve lipid
metabolism by stimulating β-oxidation and the energy expenditure
through activation of AMPK in adipocyte.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.